New York City HIV superbug: Fear or fear not?

Retrovirology

Volumn 2, Issue , 2005, Pages

  Smith, Stephen M ^a,b  

^a ST MICHAEL S MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; METHAMPHETAMINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALERTNESS; ARTICLE; DRUG EXPOSURE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MULTIDRUG RESISTANCE; PATHOGENESIS; PATIENT EDUCATION; SEXUAL INTERCOURSE; TREATMENT FAILURE; UNITED STATES; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; ADULT; ANTIVIRAL RESISTANCE; COMMUNICABLE DISEASE; DISEASE COURSE; DRUG EFFECT; HEALTH CARE PERSONNEL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MASS MEDIUM; PATHOGENICITY; PATHOPHYSIOLOGY; TIME; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COMMUNICABLE DISEASES, EMERGING; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; HEALTH PERSONNEL; HIV-1; HUMANS; MALE; MASS MEDIA; NEW YORK CITY; TIME FACTORS;

EID: 18144367374     PISSN: 17424690     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4690-2-14     Document Type: Article

References (9)

1. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, La Mar M, Wrin T, Parkin N, Poles M, Petropoulos C, Mullen M, Boden D, Ho DD: A Case of Apparent Recent Infection with a Multi-Drug-Resistant and Dual-Tropic HIV-1 in Association with Rapid Progression to AIDS: February 24; Boston. ; 2005.
2. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005, 40:468-474.
3. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JMJ, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189:2174-2180.
4. Philpott SM: HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003, 1:217-227.
5. Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP: HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002, 29:307-313.
6. Gange S, Munoz A: Variations in the Natural History of HIV Seroconverters in US Military Cohorts: February 24; Boston. ; 2005.
7. Bozzette SA: Routine screening for HIV infection - timely and cost-effective. N Engl J Med 2005, 352:620-621.
8. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP: Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 2005, 352:586-595.
9. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK: Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005, 352:570-585.